COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (NASDAQ: CLN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox in combination with Radio Frequency Ablation (RFA) treating patients with primary and metastatic liver cancer were presented at both Oral and Poster presentation at the WCIO 2008 and Best of ASCO® conference. The presentation provided Phase I interim results including safety, dosing and pharmacokinetic summaries supporting the company’s global pivotal trial in Hepatocellular Carcinoma, which is currently enrolling patients.
